PharmaMar presents positive results from a Phase II study of PM1183 in Ewing’s sarcoma

(Pharmamar) PharmaMar (MSE:PHM) has presented positive results from a Phase II study of lurbinectedin in Ewing´s sarcoma at the Connective Tissue Oncology Society´s (CTOS) International Congress that took place in Hawaii from the 8th to the 11th of November.

Comments

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

%d bloggers like this: